Source: Annual Congress 2010 - Clinical aspects of asthma and allergic respiratory diseases
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
R. Fadel, A. Khoury (Aleppo, Syrian Arab Republic). The Interest of sub-lingual immunotherapy(SLIT) in treating grasses induced asthma. Eur Respir J 2010; 36: Suppl. 54, 1379

Member's Comments

Abdulla Khouri - 26.12.2010 19:03
A nice prelenimary study , we hope you sucess

Related content which might interest you: Achievement of asthma control in patients with cold airway hyperresponsiveness at different variants of basic therapy Source: Annual Congress 2013 –Phenotyping asthma: clinical severity, comorbid conditions response to treatment? Year: 2013 Omalizumab is equally effective in persistent allergic oral corticosteroid-dependent asthma whether due to seasonal allergens or to perennial allergens Source: International Congress 2015 – Asthma and lung immunology Year: 2015 One year following a real life experience of omalizumab for moderate to severe persistent allergic asthma in Malta Source: Annual Congress 2013 –Asthma drugs: new findings Year: 2013 Clinical effectiveness of anti-IgE therapy in allergic severe asthma Source: International Congress 2014 – Asthma and COPD management Year: 2014 Specific immunotherapy with high dose grass allergen tablets was safe in grass pollen induced asthma Source: Eur Respir J 2005; 26: Suppl. 49, 134s Year: 2005 Omalizumab therapy reduces oral corticosteroid use in patients with severe allergic (IgE-mediated) asthma: European real-life experience Source: Annual Congress 2009 - Severe asthma and its treatment Year: 2009 Grass pollen allergen induces asthma symptoms in a murine model of acute allergic asthma Source: Eur Respir J 2005; 26: Suppl. 49, 587s Year: 2005 Safety of 5-grass pollen extract sublingual tablet in patients with grass pollen-induced allergic rhinoconjunctivitis and concomitant intermittent asthma: A pooled analysis Source: Annual Congress 2013 –Treatment of asthma Year: 2013 Small airways targeting of inhaled steroids for severe therapy resistant asthma in children Source: International Congress 2015 – Paediatric asthma and allergy: asthma management Year: 2015 Study of some inflammatory markers in children with moderate persistent bronchial asthma before and after therapy with inhaled corticosteroids Source: Annual Congress 2013 –Monitoring asthma: genes, cells and molecules Year: 2013 HDM sublingual AIT tablet is well-tolerated and effective in partly and uncontrolled allergic asthma Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases Year: 2014 Immunomodulatory effects of the rye grass pollen group 5 allergen on respiratory epithelial cells Source: Annual Congress 2013 –Genetics and mechanisms of, and tests for, allergy Year: 2013 Knowledge of asthma is associated with inhalation technique in elderly patients with asthma Source: International Congress 2016 – Clinical studies in asthma and immunology Year: 2016 Comparison of inspiratory flow rates using an innovative dry powder inhaler (DPI) in patients with mild–severe asthma and severe COPD Source: International Congress 2014 – Rationale behind respiratory drug development Year: 2014 The ’real-life’ long-term efficacy of omalizumab in severe persistent IgE-mediated allergic asthma in Malta Source: International Congress 2016 – Asthma management Year: 2016 Influence of basic therapy of bronchial asthma (BA) on respiratory symptoms in patients with pulmonary TB associated with bronchial asthma Source: International Congress 2014 – Tuberculosis: from epidemiology to therapy 1 Year: 2014 Effects of rosemary and platanus extracts on asthmatic subjects resistant to traditional treatments Source: Annual Congress 2013 –Novel drugs and biomarkers in respiratory medicine Year: 2013 Effect of ADRB2 gene polymorphism on treatment outcomes in asthmatics: Cold airway hyperresponsiveness and asthma control Source: International Congress 2014 – Genetics and environmental factors underlying asthma and COPD Year: 2014 Montelukast improves air trapping, not airway remodeling, in moderate-to-severe patients with asthma: A pilot tudy Source: Annual Congress 2013 –Asthma and COPD drugs: efficacy, safety and pharmacoeconomics Year: 2013 Sakuranetin treatment from baccharis retusa reduces acid mucus in a murine model of asthma Source: International Congress 2016 – Preclinical pharmacology: drug targets and mechanisms of action Year: 2016